Is Quest’s New 2036 Notes Offering and Upbeat 2026 Outlook Altering The Investment Case For Quest Diagnostics (DGX)?

• In late April 2026, Quest Diagnostics completed a US$500 million public offering of 5.00% senior unsecured notes due June 30, 2036, and reported first-quarter results showing higher sales, net income, and earnings per share versus a year earlier while raising its full-year 2026 revenue and EPS guidance.
• The company highlighted especially strong momentum in advanced diagnostics, including Alzheimer’s testing and services for end-stage renal disease and brain health, as key drivers of the improved outlook and capital-raising plans.
• Next, we’ll examine how the raised 2026 guidance, underpinned by advanced diagnostics growth, affects Quest Diagnostics’ broader investment narrative.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Quest Diagnostics Investment Narrative Recap

To own Quest Diagnostics, you need to believe that advanced diagnostics can steadily lift volumes and pricing power while technology keeps costs in check. The recent US$500 million 5.00% note issuance and raised 2026 guidance reinforce near term execution, but do not materially change the biggest risk, which remains reimbursement and policy pressure on lab pricing.

The most relevant recent announcement is the higher 2026 revenue and EPS guidance, which management tied to strength in advanced testing such as Alzheimer’s, end stage renal disease, and brain health. This supports the core catalyst of expanding higher value testing, even as the company faces ongoing exposure to government and exchange based payers and potential pricing headwinds.

Yet against this stronger outlook, investors should be aware that reimbursement and policy shifts could still...

Read the full narrative on Quest Diagnostics (it's free!)

Quest Diagnostics’ narrative projects $12.8 billion revenue and $1.3 billion earnings by 2029. This requires 5.0% yearly revenue growth and an earnings increase of about $300 million from $988.0 million.

Uncover how Quest Diagnostics' forecasts yield a $218.19 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$218 to US$307 per share, showing wide dispersion in expectations. Against this backdrop, the raised 2026 guidance anchored in advanced diagnostics growth gives you one more lens on how Quest’s execution may influence future performance, but it is worth weighing alongside those diverse community views.

Explore 2 other fair value estimates on Quest Diagnostics - why the stock might be worth just $218.19!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Quest Diagnostics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Quest Diagnostics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Quest Diagnostics' overall financial health at a glance.

Searching For A Fresh Perspective?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com